Sino-Argi Leading Biosciences (603970) — Working Capital to Net Assets Ratio
Sino-Argi Leading Biosciences (603970) has a Working Capital to Net Assets ratio of 86.6% as of March 2026. Working capital of CN¥1.54 Billion (current assets of CN¥6.28 Billion minus current liabilities of CN¥4.74 Billion) is measured against net assets of CN¥1.78 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Sino-Argi Leading Biosciences (603970) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Sino-Argi Leading Biosciences Working Capital to Net Assets (2012–2025)
This chart shows how Sino-Argi Leading Biosciences's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 86.6%, reflecting working capital of CN¥1.54 Billion against net assets of CN¥1.78 Billion CNY. Check Sino-Argi Leading Biosciences tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Sino-Argi Leading Biosciences (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Sino-Argi Leading Biosciences from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Sino-Argi Leading Biosciences.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 86.5% | CN¥1.50 Billion | CN¥1.73 Billion | CN¥4.65 Billion | CN¥3.15 Billion | ▲ +0.2 pp |
| 2024 | 86.3% | CN¥1.45 Billion | CN¥1.68 Billion | CN¥5.35 Billion | CN¥3.90 Billion | ▲ +1.6 pp |
| 2023 | 84.7% | CN¥1.35 Billion | CN¥1.59 Billion | CN¥5.74 Billion | CN¥4.39 Billion | ▼ -6.0 pp |
| 2022 | 90.8% | CN¥1.35 Billion | CN¥1.48 Billion | CN¥5.98 Billion | CN¥4.63 Billion | ▲ +6.8 pp |
| 2021 | 83.9% | CN¥1.07 Billion | CN¥1.28 Billion | CN¥4.50 Billion | CN¥3.43 Billion | ▼ -1.1 pp |
| 2020 | 85.1% | CN¥972.54 Million | CN¥1.14 Billion | CN¥3.83 Billion | CN¥2.86 Billion | ▲ +0.9 pp |
| 2019 | 84.1% | CN¥878.76 Million | CN¥1.04 Billion | CN¥2.55 Billion | CN¥1.68 Billion | ▲ +2.1 pp |
| 2018 | 82.0% | CN¥784.71 Million | CN¥957.07 Million | CN¥2.39 Billion | CN¥1.61 Billion | ▲ +2.3 pp |
| 2017 | 79.7% | CN¥690.46 Million | CN¥866.35 Million | CN¥2.58 Billion | CN¥1.89 Billion | ▼ -42.1 pp |
| 2016 | 121.8% | CN¥525.44 Million | CN¥431.42 Million | CN¥2.42 Billion | CN¥1.89 Billion | ▲ +16.0 pp |
| 2015 | 105.8% | CN¥364.44 Million | CN¥344.56 Million | CN¥2.45 Billion | CN¥2.08 Billion | ▼ -54.7 pp |
| 2014 | 160.5% | CN¥466.06 Million | CN¥290.44 Million | CN¥1.92 Billion | CN¥1.45 Billion | ▲ +43.4 pp |
| 2013 | 117.1% | CN¥307.50 Million | CN¥262.68 Million | CN¥1.62 Billion | CN¥1.31 Billion | ▲ +26.6 pp |
| 2012 | 90.4% | CN¥218.54 Million | CN¥241.63 Million | CN¥1.21 Billion | CN¥990.93 Million | — |